Advanced Search

Refractory Acute Myeloid Leukemia Stocks List

Symbol Grade Name % Change
CRBU B Caribou Biosciences, Inc. 8.58
XBIO C Xenetic Biosciences, Inc. 7.58
MBRX D Moleculin Biotech, Inc. 1.61
SYRS F Syros Pharmaceuticals, Inc. -14.38
View As Page of Charts
Related Industries: Biotechnology
Related Stock Lists: Acute Myeloid Leukemia Biopharmaceutical Biotechnology Cancer Leukemia Medicine Treatment Of Relapsed Or Refractory Acute Myeloid Leukemia Acute Leukemia Anemia Anthracycline Antineoplastic Drugs Blastoma Breakthrough Therapy Cancer Immunotherapy CD19 Cell Biology Cell Therapy Chemotherapy Chimeric Antigen Receptor T Cell Chronic Kidney Disease

Related ETFs - A few ETFs which own one or more of the above listed Refractory Acute Myeloid Leukemia stocks.

Symbol Grade Name Weight
XDNA C Kelly CRISPR & Gene Editing Technology ETF 5.23
CNCR C Loncar Cancer Immunotherapy ETF 2.88
CBLS C Changebridge Capital Long/Short Equity ETF 2.86
CBSE B Changebridge Capital Sustainable Equity ETF 2.14
GNOM C Global X Genomics & Biotechnology ETF 0.85
View all Refractory Acute Myeloid Leukemia ETFs...
Compare ETFs
Compare CBSE to GNOM Compare CNCR to GNOM Compare XDNA to CBSE

Refractory Acute Myeloid Leukemia Stocks Recent News

Date Stock Title
May 16 SYRS Syros Pharmaceuticals, Inc. (SYRS) CEO Nancy Simonian on Q1 2022 Results - Earnings Call Transcript
May 16 SYRS Syros Pharmaceuticals, Inc. (SYRS) Reports Q1 Loss, Tops Revenue Estimates
May 16 SYRS Syros Pharmaceuticals GAAP EPS of -$0.40 beats by $0.07, revenue of $5.47M beats by $0.55M
May 16 SYRS Syros Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides a Corporate Update
May 16 SYRS Earnings Scheduled For May 16, 2022
May 13 SYRS Syros Pharmaceuticals Q1 2022 Earnings Preview
May 13 SYRS Strength Seen in Immatics (IMTX): Can Its 5.3% Jump Turn into More Strength?
May 12 XBIO Xenetic Biosciences reports Q1 results
May 12 XBIO Xenetic Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update
May 12 CRBU Caribou extends gains as SVB Leerink raises target after early data for CAR-T asset
May 12 CRBU Caribou's Lymphoma Candidate Shows 100% Response Rate In Early-Stage Study
May 12 CRBU Caribou Biosciences rises 27% on early-stage CAR-T therapy data for non-Hodgkin lymphoma
May 12 CRBU Caribou Biosciences Announces Positive Initial Data for CB-010 Anti-CD19 Allogeneic CAR-T Cell Therapy
May 12 MBRX Moleculin Biotech GAAP EPS of -$0.24 misses by $0.01
May 12 MBRX Moleculin Reports First Quarter 2022 Financial Results and Provides Programs Update
May 12 CRBU Here's What Analysts Are Forecasting For Caribou Biosciences, Inc. (NASDAQ:CRBU) After Its First-Quarter Results
May 11 CRBU Caribou Biosciences Announces Appointment of David Johnson to its Board of Directors
May 11 SYRS 10 Stocks to Invest in Under $20 According to Michael Castor’s Sio Capital
May 10 MBRX Moleculin Receives Approval from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for Protocol Amendment to Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19
Related Industries: Biotechnology
Related Stock Lists: Acute Myeloid Leukemia Biopharmaceutical Biotechnology Cancer Leukemia Medicine Treatment Of Relapsed Or Refractory Acute Myeloid Leukemia Acute Leukemia Anemia Anthracycline Antineoplastic Drugs Blastoma Breakthrough Therapy Cancer Immunotherapy CD19 Cell Biology Cell Therapy Chemotherapy Chimeric Antigen Receptor T Cell Chronic Kidney Disease

Browse All Tags